Patients with Inflammatory Bowel Disease are at Increased Risk for Complications of Herpes Zoster.

Herpes Zoster Inflammatory bowel disease immunosuppression vaccines

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
24 Oct 2024
Historique:
received: 21 11 2023
revised: 25 07 2024
accepted: 06 09 2024
medline: 27 10 2024
pubmed: 27 10 2024
entrez: 26 10 2024
Statut: aheadofprint

Résumé

Patients with inflammatory bowel disease (IBD) are at an increased risk for vaccine-preventable diseases, such as herpes zoster (HZ). The aim of this study was to determine whether complications of HZ are more frequent in patients with IBD than in non-IBD controls. This was a retrospective, cohort study using the Optum Research Database. Patients with IBD were matched 1:1 to non-IBD controls based on age, sex, and index year, which was defined as the diagnosis of HZ. We then identified the complications of HZ that occurred up to 90 days after the index date. We compared patients with IBD with non-IBD controls and evaluated the 90-day risk of HZ complications. We used a composite primary outcome for any HZ complication. Secondary outcomes were risk factors for complications. Four thousand seven fifty-six patients with IBD met the inclusion criteria and were matched to the controls. Patients with IBD were more likely to have complications of HZ than controls [738 (15.52%) vs. 595 (12.51%), p < 0.0001]. Patients with IBD with higher comorbidity scores were more likely to develop complications (1.86 vs. 1.18 p < 0.0001). In the logistic regression analysis of patients with IBD having a higher comorbidity score, above 50 years of age, on anti-TNF or corticosteroids were all at increased risk of a complication of HZ. Patients with IBD are more likely to have complications of HZ than controls. Efforts are needed to increase HZ vaccine uptake to reduce the morbidity of HZ.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Patients with inflammatory bowel disease (IBD) are at an increased risk for vaccine-preventable diseases, such as herpes zoster (HZ). The aim of this study was to determine whether complications of HZ are more frequent in patients with IBD than in non-IBD controls.
METHODS METHODS
This was a retrospective, cohort study using the Optum Research Database. Patients with IBD were matched 1:1 to non-IBD controls based on age, sex, and index year, which was defined as the diagnosis of HZ. We then identified the complications of HZ that occurred up to 90 days after the index date. We compared patients with IBD with non-IBD controls and evaluated the 90-day risk of HZ complications. We used a composite primary outcome for any HZ complication. Secondary outcomes were risk factors for complications.
RESULTS RESULTS
Four thousand seven fifty-six patients with IBD met the inclusion criteria and were matched to the controls. Patients with IBD were more likely to have complications of HZ than controls [738 (15.52%) vs. 595 (12.51%), p < 0.0001]. Patients with IBD with higher comorbidity scores were more likely to develop complications (1.86 vs. 1.18 p < 0.0001). In the logistic regression analysis of patients with IBD having a higher comorbidity score, above 50 years of age, on anti-TNF or corticosteroids were all at increased risk of a complication of HZ.
CONCLUSION CONCLUSIONS
Patients with IBD are more likely to have complications of HZ than controls. Efforts are needed to increase HZ vaccine uptake to reduce the morbidity of HZ.

Identifiants

pubmed: 39461467
pii: S1542-3565(24)00960-1
doi: 10.1016/j.cgh.2024.09.022
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Freddy Caldera (F)

Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, WI, USA. Electronic address: fcaldera@medicine.wisc.edu.

Siddharth Singh (S)

Division of Gastroenterology, University of California San Diego, La Jolla, California, Division of Biomedical Informatics, University of California San Diego, La Jolla, California.

Emily E Zona (EE)

University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.

Oscar Ramirez Ramirez (O)

Department Medicine, Division of Internal Medicine, University of Wisconsin- Madison School of Medicine & Public Health, Madison, WI, USA.

Jonathan Inselman (J)

Division of Health Care Delivery Research, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA.

Herbert Heien (H)

Division of Health Care Delivery Research, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA.

Andrew P Keaveny (AP)

Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL.

Mary S Hayney (MS)

School of Pharmacy, University of Wisconsin--Madison, School of Medicine & Public Health.

Francis A Farraye (FA)

Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL.

Classifications MeSH